Researchers conducting the phase 3 ‘Exenatide PD3’ clinical trial have published the protocol of the study, which outlines the details of the trial.

Cure Parkinson’s has supported the clinical development of exenatide in people with Parkinson’s from the very beginning and has been instrumental in setting up the next phase of testing, the ‘Exenatide-PD3’ study. The protocol of the study, providing all of the details of how the study will be conducted, has now been published.

Exenatide PD3 is a two-year study, funded by the National Institute for Health Research, and is currently recruiting 200 people with Parkinson’s at research centres in London, Plymouth, Edinburgh, Oxford and Manchester. Cure Parkinson’s is funding two key sub-studies within the phase 3 trial.

These ‘added value’ sub-studies will provide more in-depth data for the researchers in the Exenatide PD3 study and help improve clinical trials focused on disease-modification for Parkinson’s in the future.

Our monthly e-newsletter

The best way to stay up to date with all our research news is to sign up to our monthly newsletter

Sign up now

How helpful was this content?

/ 5. Vote count:

We are sorry that this content was not useful for you

Let us improve this content

Can you tell us how we can improve this content?